September 2016

Sekisui XenoTech Joins Fight Against Liver Disease

Author:  Dr. Maciej Czerwinski, Michael Millhollen
Posted:  16 September 2016

Sekisui XenoTech is committed to furthering the knowledge surrounding hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), which affects one out of four people worldwide. Our Research BioBank is designed to provide diseased and normal pre-lysate tissue as well as disease-diagnosed hepatocytes for scientific investigation at a reasonable cost to the end user. Our tissue is collected with the initial intent for transplant, thus making it a perfect candidate to advance basic medical science and contribute to the development of new treatments. The pre-lysate tissue samples in Sekisui XenoTech's Research BioBank allow for the analysis of drug target expression and early markers of fatty liver diseases across diverse US populations. Pathologic diagnosis and donor demographics, BMI, history of diabetes and alcohol use data, along with representative microphotographs, are available for each specimen...

Learn more about Sekisui XenoTech's Research BioBank

Comments
Blog post currently doesn't have any comments.
Give Feedback